Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 10, 2016, Pages 1247-1257

  Van der Veken, Bieke ^a   De Meyer, Guido R Y ^a   Martinet, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

animal model; Atherosclerosis; cell metabolism; imaging; neoangiogenesis; neovascularization; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; FATTY ACID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL METABOLISM; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; IN VIVO STUDY; INFLAMMATION; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; HEMORRHAGE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FATTY ACIDS; GLYCOLYSIS; HEMORRHAGE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC;

EID: 84987932384     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2016.1186650     Document Type: Review

References (112)

1. P.Libby Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.• An excellent review about inflammation in atherogenesis and advanced atherosclerosis.
2. A.Pirillo, G.D.Norata, A.L.Catapano. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786.
3. M.I.Cybulsky, M.A.Gimbrone. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–791.
4. M.J.Davies, J.L.Gordon, A.J.Gearing, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223–229.
5. E.Galkina, K.Ley. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292–2301.
6. Y.V.Bobryshev. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37:208–222.
7. P.Libby. Changing concepts of atherogenesis. J Intern Med. 2000;247:349–358.
8. L.Song, C.Leung, C.Schindler. Lymphocytes are important in early atherosclerosis. J Clin Invest. 2001;108:251–259.
9. O.Deboer, A.Becker, A.Vanderwal. T lymphocytes in atherogenesis-functional aspects and antigenic repertoire. Cardiovasc Res. 2003;60:78–86.
10. A.V.Finn, M.Nakano, J.Narula, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–1292.
11. R.Virmani, F.D.Kolodgie, A.P.Burke, et al. Atherosclerotic plaque progression and vulnerability to rupture:angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054–2061.•• This article highlights the importance of intraplaque neovascularization and subsequent intraplaque hemorrhage in plaque destabilization.
12. F.D.Kolodgie, A.P.Burke, A.Farb, et al. The thin-cap fibroatheroma:a type of vulnerable plaque:the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–292.
13. M.Naghavi, P.Libby, E.Falk, et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:part I. Circulation. 2003;108:1664–1672.
14. R.Virmani, A.P.Burke, A.Farb, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–C18.•• This review covers all aspects of vulnerable atherosclerotic plaques.
15. W.E.Hellings, W.Peeters, F.L.Moll, et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome:a prognostic study. Circulation. 2010;121:1941–1950.
16. P.Carmeliet. Angiogenesis in health and disease:therapeutic opportunities. Nat Med. 2002;66:653–660.•• A comprehensive review of the molecular processes and therapeutic options in angiogenesis.
17. W.Koester. Endarteritis and arteritis. Berl Klin Woshenschr. 1876;13:454–455.
18. M.C.Winternitz, R.M.Thomas, P.M.LeCompte. The biology of arteriosclerosis. Springfield, IL:Charles C. Thomas; 1938.
19. J.C.Patterson. Capillary rupture with intimal hemmorhage as a caustive factor in coronary thrombosis. Arch Pathol. 1938;25:474–487.
20. J.C.Sluimer, F.D.Kolodgie, A.P.Bijnens, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009;53:1517–1527.• This article emphasizes the importance of compromised integrity of intraplaque microvessels in plaque destabilization.
21. M.M.Kockx, K.M.Cromheeke, M.W.M.Knaapen, et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:440–446.
22. B.J.Dunmore, M.J.McCarthy, A.R.Naylor, et al. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg. 2007;45:155–159.
23. P.R.Moreno, K.R.Purushothaman, V.Fuster, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta:implications for plaque vulnerability. Circulation. 2004;110:2032–2038.• This study consolidates the significance of intraplaque neovessels in advanced human atherosclerotic plaques.
24. J.-B.Michel, R.Virmani, E.Arbustini, et al. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J. 2011;32:1977–1985. 1985a, 1985b, 1985c.
25. E.Geiringer. Intimal vascularization and atherosclerosis. J Pathol Bacteriol. 1951;63:201–211.
26. W.H.G.Seymour. Comparison of abdominal and thoracic aortic medial structure in mammals. Circ Res. 1969;25:677–686.
27. R.H.Thomlinson, L.H.Gray. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539–549.
28. J.C.Sluimer, M.J.Daemen. Novel concepts in atherogenesis:angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:27–29.• This paper describes plaque hypoxia as a crucial initiator of intraplaque neovascularization.
29. N.Ferrara. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280:C1358–C1366.
30. T.Cohen, D.Nahari, L.W.Cerem, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736–741.
31. A.G.Arroyo, M.L.Iruela-Arispe. Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res. 2010;86:226–235.
32. F.De Smet, I.Segura, K.De Bock, et al. Mechanisms of vessel branching:filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol. 2009;29:639–649.
33. S.P.Herbert, D.Y.R.Stainier. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12:551–564.• This review scrutinizes the different aspects of endothelial cell behavior during angiogenesis.
34. M.Potente, H.Gerhardt, P.Carmeliet. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–887.
35. R.Blanco, H.Gerhardt. VEGF and notch in tip and stalk cell selection. Cold Spring Harb Perspect Med. 2013;3:a006569.
36. J.Pelisek, G.Well, C.Reeps, et al. Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ J. 2012;76:1274–1282.
37. J.J.Boyle, H.A.Harrington, E.Piper, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol. 2009;174:1097–1108.
38. G.R.Y.De Meyer, D.M.M.De Cleen, S.Cooper, et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res. 2002;90:1197–1204.
39. A.V.Finn, M.Nakano, R.Polavarapu, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59:166–177.
40. G.L.Wang, B.H.Jiang, E.A.Rue, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510–5514.
41. C.W.Pugh, P.J.Ratcliffe. Regulation of angiogenesis by hypoxia:role of the HIF system. Nat Med. 2003;9:677–684.
42. J.Yang, L.Zhang, P.J.A.Erbel, et al. Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor. J Biol Chem. 2005;280:36047–36054.
43. J.E.Ziello, I.S.Jovin, Y.Huang. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007;80:51–60.
44. M.-P.Simon, R.Tournaire, J.Pouyssegur. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol. 2008;217:809–818.
45. T.Higashida, H.Kanno, M.Nakano, et al. Expression of hypoxia-inducible angiogenic proteins (hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and E26 transformation-specific-1) and plaque hemorrhage in human carotid atherosclerosis. J Neurosurg. 2008;109:83–91.
46. K.Türeyen, R.Vemuganti, M.S.Salamat, et al. Increased angiogenesis and angiogenic gene expression in carotid artery plaques from symptomatic stroke patients. Neurosurg. 2006;58:971–977.
47. M.J.Cross, J.Dixelius, T.Matsumoto, et al. VEGF-receptor signal transduction. Trends Biochem Sci. 2003;28:488–494.
48. M.Inoue, H.Itoh, M.Ueda, et al. Vascular Endothelial Growth Factor (VEGF) expression in human coronary atherosclerotic lesions:possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98:2108–2116.
49. J.Gavard, J.S.Gutkind. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–1234.
50. R.Khurana, L.Moons, S.Shafi, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111:2828–2836.
51. J.E.Park, H.H.Chen, J.Winer, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269:25646–25654.
52. K.Pilarczyk, K.J.E.Sattler, O.Galili, et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis. 2008;196:333–340.
53. F.Zhang, Z.Tang, X.Hou, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci. 2009;106:6152–6157.
54. S.Jauhiainen, S.-K.Häkkinen, P.I.Toivanen, et al. Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects. Arterioscler Thromb Vasc Biol. 2011;31:1617–1624.
55. A.V.Benest, S.J.Harper, S.Y.Herttuala, et al. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res. 2008;78:315–323.
56. D.Qin, T.Trenkwalder, S.Lee, et al. Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. PLoS One. 2013;8:e61831.
57. E.Brogi, J.Winkles, R.Underwood, et al. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest. 1993;92:2408–2418.
58. S.E.Hughes. Localisation and differential expression of the Fibroblast Growth Factor Receptor (FGFR) multigene family in normal and atherosclerotic human arteries. Cardiovasc Res. 1996;32:557–569.
59. S.Davis, G.D.Yancopoulos. The angiopoietins:Yin and Yang in angiogenesis. Curr Top Microbiol Immunol. 1999;237:173–185.
60. Y.Brudno, A.B.Ennett-Shepard, R.R.Chen, et al. Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials. 2013;34:9201–9209.
61. M.Hellstrom, H.Gerhardt, M.Kalen, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543–554.
62. X.Liu, Y.Chen, F.Zhang, et al. Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium. Scand Cardiovasc J. 2007;41:95–101.
63. H.Su, J.Takagawa, Y.Huang, et al. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. Int J Cardiol. 2009;133:191–197.
64. K.Norrby. Mast cells and angiogenesis. APMIS. 2002;110:355–371.
65. A.Simonini, M.Moscucci, D.Muller, et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 2000;101:1519–1526.
66. A.Bobik, A.Agrotis, P.Kanellakis, et al. Distinct patterns of transforming growth factor- isoform and receptor expression in human atherosclerotic lesions:colocalization implicates TGF- in fibrofatty lesion development. Circulation. 1999;99:2883–2891.
67. H.Ma, T.M.Calderon, J.T.Fallon, et al. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis. 2002;164:79–87.
68. A.Bikfalvi. Platelet factor 4:an inhibitor of angiogenesis. Semin Thromb Hemost. 2004;30:379–385.
69. M.S.O’Reilly, T.Boehm, Y.Shing, et al. Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285.
70. M.O’Reilly. Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell. 1994;79:315–328.
71. X.Xu, W.Mao, Y.Chai, et al. Angiogenesis inhibitor, endostar, prevents vasa vasorum neovascularization in a swine atherosclerosis model. J Atheroscler Thromb. 2015;22:1100–1112.
72. Y.Sato, H.Sonoda. The vasohibin family:a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:37–41.
73. R.Fukumitsu, M.Minami, K.Yoshida, et al. Expression of vasohibin-1 in human carotid atherosclerotic plaque. J Atheroscler Thromb. 2015;22:942–948.
74. K.S.Moulton, E.Heller, M.A.Konerding, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726–1732.
75. Y.Zhang, W.J.Cliff, G.I.Schoefl, et al. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993;143:164–172.
76. A.J.Beer, J.Pelisek, P.Heider, et al. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging. 2014;7:178–187.
77. S.Schoors, U.Bruning, R.Missiaen, et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature. 2015;520:192–197.
78. K.De Bock, M.Georgiadou, S.Schoors, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651–663.
79. J.M.Tarkin, F.R.Joshi, J.H.F.Rudd. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11:443–457.
80. N.V.Joshi, A.T.Vesey, M.C.Williams, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques:a prospective clinical trial. Lancet. 2014;383:705–713.
81. J.Sun Yoo, J.Lee, J.Ho Jung, et al. SPECT/CT imaging of high-risk atherosclerotic plaques using integrin-binding RGD dimer peptides. Sci Rep. 2015;5:11752.
82. S.B.Feinstein. The powerful microbubble:from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol. 2004;287:H450–H457.
83. Z.Akkus, G.Van burken, S.C.H.Van den Oord, et al. Carotid intraplaque neovascularization quantification software (CINQS). IEEE J Biomed Heal Informatics. 2015;19:332–338.
84. S.C.H.Van den Oord, Z.Akkus, J.G.Bosch, et al. Quantitative contrast-enhanced ultrasound of intraplaque neovascularization in patients with carotid atherosclerosis. Ultraschall Med. 2014;36:154–161.
85. C.Giannarelli, B.Ibanez, G.Cimmino, et al. Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. JACC Cardiovasc Imaging. 2010;3:1256–1264.
86. G.L.Ten Kate, S.C.H.Van den Oord, E.J.G.Sijbrands, et al. Current status and future developments of contrast-enhanced ultrasound of carotid atherosclerosis. J Vasc Surg. 2013;57:539–546.
87. S.Coli, M.Magnoni, G.Sangiorgi, et al. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries:correlation with histology and plaque echogenicity. J Am Coll Cardiol. 2008;52:223–230.
88. F.L.Celletti, J.M.Waugh, P.G.Amabile, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425–429.
89. K.Ohtani, K.Egashira, K.Hiasa, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation. 2004;110:2444–2452.
90. R.Hutter, W.S.Speidl, C.Valdiviezo, et al. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1α activation:a novel aspect of angiogenesis in atherosclerosis. J Cardiovasc Transl Res. 2013;6:558–569.
91. M.C.Kowala, R.Recce, S.Beyer, et al. Characterization of atherosclerosis in LDL receptor knockout mice:macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis. 2000;149:323–330.
92. Y.Nakashima, A.S.Plump, E.W.Raines, et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol. 1994;14:133–140.
93. M.Lucerna, A.Zernecke, R.de Nooijer, et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood. 2007;109:122–129.
94. J.H.P.Lardenoye. Accelerated atherosclerosis and calcification in vein grafts:a study in APOE*3 leiden transgenic mice. Circ Res. 2002;91:577–584.
95. M.R.de Vries, H.W.M.Niessen, C.W.G.M.Löwik, et al. Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PLoS One. 2012;7:e47134.
96. J.L.Van Herck, G.R.Y.De Meyer, W.Martinet, et al. Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice. Circulation. 2009;120:2478–2487.
97. C.Van der Donckt, J.L.Van Herck, D.M.Schrijvers, et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J. 2015;36:1049–1058.• This study describes a unique mouse model of atherosclerotic plaque rupture. Plaques in this mouse model show intraplaque neovascularization due to elastin fiber fragmentation.
98. A.D.Hauer, G.H.M.Van Puijvelde, N.Peterse, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2050–2057.
99. S.Winnik, C.Lohmann, G.Siciliani, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis–implications for cardiovascular safety. Int J Cardiol. 2013;168:2453–2461.
100. C.Stefanadis, K.Toutouzas, E.Stefanadi, et al. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent:an experimental study. Atherosclerosis. 2007;195:269–276.
101. K.S.Moulton, K.Vakili, D.Zurakowski, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100:4736–4741.
102. H.Sallinen, M.Anttila, J.Narvainen, et al. Antiangiogenic gene therapy with soluble VEGFR-1, −2, and −3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278–284.
103. T.Kamba, D.M.McDonald. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795.
104. S.Lien, H.B.Lowman. Therapeutic anti-VEGF antibodies. In:Chernajovsky Y, Nissim A, editors. Therapeutic antibodies, Vol. 181. Berlin:Springer;. 2008. p. 131–150.
105. M.R.de Vries, R.C.de Jong, E.A.Peters, et al. Abstract 642:vascular endothelial growth factor receptor 2 blockade in murine vein graft ameliorates lesion growth and enhances plaque stability by reducing intraplaque hemorrhage. Arter Thromb Vasc Biol. 2014;34:A642.
106. K.J.Gotink, H.M.W.Verheul. Anti-angiogenic tyrosine kinase inhibitors:what is their mechanism of action? Angiogenesis. 2010;13:1–14.
107. B.Clem, S.Telang, A.Clem, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7:110–120.
108. S.Schoors, K.De Bock, A.R.Cantelmo, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014;19:37–48•• This paper contains innovative data about glycolysis in endothelial cells and indicates that cell metabolism is a promising target to inhibit pathological angiogenesis.
109. M.Seo, Y.-H.Lee. PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer. J Mol Biol. 2014;426:830–842.
110. M.Weis. Statins have biphasic effects on angiogenesis. Circulation.2002;105:736–745.
111. L.Roth, M.Rombouts, D.M.Schrijvers, et al. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a novel murine model of atherosclerotic plaque rupture. Atherosclerosis. 2016;244:e2–e3.
112. P.D.Adamson, M.R.Dweck, D.E.Newby. The vulnerable atherosclerotic plaque:in vivo identification and potential therapeutic avenues. Heart. 2015;101:1755–1766.